Pascal Soriot
- All
- News
- Videos
-
Top UK CEOs Have Already Earned More Money Than Average Workers Will All Year
These findings have sparked concerns about income inequality and the impact of high CEO pay on the broader economy.
-
AstraZeneca's Pascal Soriot: The Man Behind The Vaccine
Pascal Soriot has led the charge to make AstraZeneca one of the first pharmaceutical companies in the world to produce a vaccine against Covid-19.
-
Oxford Vaccine Will Protect 95 Per Cent, Says AstraZeneca CEO: Report
The Oxford coronavirus vaccine will "protect 95 per cent of patients" and is "as effective as the Pfizer and Moderna" alternatives, Pascal Soriot, the chief executive of AstraZeneca, told British daily The Sunday Times
-
Lower First Dose Means More People Can Be Vaccinated Faster: AstraZeneca
AstraZeneca's chief executive officer Pascal Soriot said on Monday that the lower first dose of its experimental COVID-19 vaccine meant more people can be vaccinated more quickly, as the British drugmaker unveiled interim late-stage trial results.
-
AstraZeneca Leaves Door Ajar to Pfizer, Despite Hurdles
Chief executive Pascal Soriot stressed his company had a bright future as a stand-alone firm but acknowledged that shareholders would expect AstraZeneca's board to negotiate if terms were sufficiently attractive in a sweetened offer.
-
Pfizer Chief Enters Lion's Den of UK Politics to Sell AstraZeneca Deal
The boss of US drugmaker Pfizer faces UK lawmakers on Tuesday with a promise and a threat - to protect British jobs in his proposed joint creation with AstraZeneca of a global powerhouse upon which he says the latter's future depends.
-
Pfizer Presses AstraZeneca Case as CEO Faces UK Grilling
US drugmaker Pfizer pressed the scientific case for its controversial plan to acquire AstraZeneca on Monday as its chief executive prepared for a grilling from British lawmakers.
-
AstraZeneca to axe 1,600 jobs in major R&D overhaul
AstraZeneca is likely to cut around 1,600 jobs as it overhauls it research operations and consolidates drug development work in three major centres.
-
Top UK CEOs Have Already Earned More Money Than Average Workers Will All Year
These findings have sparked concerns about income inequality and the impact of high CEO pay on the broader economy.
-
AstraZeneca's Pascal Soriot: The Man Behind The Vaccine
Pascal Soriot has led the charge to make AstraZeneca one of the first pharmaceutical companies in the world to produce a vaccine against Covid-19.
-
Oxford Vaccine Will Protect 95 Per Cent, Says AstraZeneca CEO: Report
The Oxford coronavirus vaccine will "protect 95 per cent of patients" and is "as effective as the Pfizer and Moderna" alternatives, Pascal Soriot, the chief executive of AstraZeneca, told British daily The Sunday Times
-
Lower First Dose Means More People Can Be Vaccinated Faster: AstraZeneca
AstraZeneca's chief executive officer Pascal Soriot said on Monday that the lower first dose of its experimental COVID-19 vaccine meant more people can be vaccinated more quickly, as the British drugmaker unveiled interim late-stage trial results.
-
AstraZeneca Leaves Door Ajar to Pfizer, Despite Hurdles
Chief executive Pascal Soriot stressed his company had a bright future as a stand-alone firm but acknowledged that shareholders would expect AstraZeneca's board to negotiate if terms were sufficiently attractive in a sweetened offer.
-
Pfizer Chief Enters Lion's Den of UK Politics to Sell AstraZeneca Deal
The boss of US drugmaker Pfizer faces UK lawmakers on Tuesday with a promise and a threat - to protect British jobs in his proposed joint creation with AstraZeneca of a global powerhouse upon which he says the latter's future depends.
-
Pfizer Presses AstraZeneca Case as CEO Faces UK Grilling
US drugmaker Pfizer pressed the scientific case for its controversial plan to acquire AstraZeneca on Monday as its chief executive prepared for a grilling from British lawmakers.
-
AstraZeneca to axe 1,600 jobs in major R&D overhaul
AstraZeneca is likely to cut around 1,600 jobs as it overhauls it research operations and consolidates drug development work in three major centres.
